Lantern Pharma 10-Q: Second Nasdaq Deficiency, CEO Exit and $2M Settlement Accrual
LTRN is trading near its 52-week low of $0.362 (0.8% above the low) on light trading volume (0.4× avg).
Summary
Lantern Pharma's Q3 10-Q discloses a second Nasdaq deficiency (sub-$1.00 bid), the November 15 resignation of CEO Panna Sharma with CFO David Margrave as interim, and a $2,000,000 proposed settlement accrual — all while cash of about $7.6M fails to cover 12 months of operations.
Key Events · Legal and Risk Events · LTRN
-
Second Nasdaq Deficiency Notice
On November 13, 2026, Nasdaq notified the company that its bid price had closed below $1.00 for 30 consecutive business days; it has until May 12, 2027 to regain compliance, with a possible second 180-day period requiring a reverse split. This sits alongside the previously disclosed $35 million market value shortfall, for which the deadline is March 24, 2027.
-
CEO Resigns, CFO Takes Interim Role
Panna Sharma resigned as President, CEO and director effective November 15, 2026. CFO David Margrave was appointed Interim CEO effective November 16, 2026 while the board searches for a permanent successor.
-
$2M Settlement Accrued
A proposed settlement with a former part-time consultant over disability discrimination and sexual harassment claims would pay $2,000,000: $1,000,000 within 30 days of effectiveness and $1,000,000 upon raising at least $10,000,000 in gross proceeds or the two-year anniversary. The full $2,000,000 is accrued, but the agreement is not yet final.
-
Cash Runway Under 12 Months
Cash, cash equivalents and marketable securities totaled about $7,627,000 at September 30, 2026, with working capital of about $2,759,000. Management states this will not fund operating expenses and capital expenditures for 12 months, raising substantial doubt about going concern absent new funding.
Analysis · LTRN · Life Sciences
Three first-time disclosures land in one filing at a company already fighting for its listing. On November 13, 2026, Nasdaq issued a second deficiency notice: the bid price has closed below $1.00 for 30 straight business days, and the company has until May 12, 2027 to cure — on top of the $35 million market value shortfall already disclosed. Separately, CEO Panna Sharma resigned November 15 and the board handed the job to CFO David Margrave on an interim basis, leaving the top executive slot open while a permanent replacement is sought. The company also booked a $2,000,000 accrual for a proposed settlement of a former consultant's harassment and discrimination claims — $1,000,000 payable within 30 days of effectiveness and $1,000,000 more only if the company raises at least $10,000,000 or two years pass. Against that, cash, equivalents and marketable securities of roughly $7,627,000 will not fund operations for 12 months, so another raise is required. The $696,615 of third-quarter net income is an accounting artifact: a $6,044,661 non-cash gain from marking the May 2026 warrants down as the share price fell, not operating profit.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LTRN was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.36 to $4.34. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.